UNSPSC 51433910: Palonidipine

This classification denotes a calcium channel blocker with the molecular formula C29H34FN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FMS4X67Q96, chemically known as (- )-3-(benzylmethyl-amino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate. but generally known as palonidipine, which bears US NIH Compound Identifier 119154. European Medicines Agency schedules Palonidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09592MIG.

UNSPSC 51433910 Palonidipine, a Commodity code, captures pharmaceutical procurement for state and local emergency medical services, health agencies, and cooperative purchasing alliances. State and local governments buy branded and generic medications—primarily advanced life support drugs, multi-source generics, and over-the-counter products—through sealed-bid procurements, requests for proposals, and cooperative purchasing agreements. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing organizations. The scope spans acquisition of specific line-item medications (individual drug vials and injections in specified strengths and dosages) for emergency medical services use, as well as broader manufacturer agreements for generic pharmaceuticals distributed through authorized wholesalers across multiple jurisdictions and facilities. Vendors must comply with FDA manufacturing standards, Drug Supply Chain Security Act requirements, and current Good Manufacturing Practices, and provide Safety Data Sheets and accessibility documentation where required.

Activity spans Florida, Texas, Minnesota, and Oregon, with recent solicitations showing both direct municipal procurement and multistate cooperative contracting models. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB 26-P-00188, due April 8, 2026) for Tampa Fire Rescue, requesting 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials with a $40,000 estimated value and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for Generic Multi-Source Pharmaceuticals and OTC Products (due March 26, 2026) covering state and local government facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026 and contract terms of two years plus optional extensions. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) exploring direct-to-manufacturer prescription relationships outside traditional pharmacy benefit managers and wholesalers, signaling potential future formal procurement on direct-contracting models.